1. Laml T, Schulz-Lobmeyr I, Obruca A, et al. Prematureovarian failure: etiology and prospects. Gynecol Endocrinol 2000; 14: 292-302.
2. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 2007; 12: 1044–54.
3. Blumenfeld Z, Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr 2005; 34: 40–3.
4. Blumenfeld Z, Shapiro D, Shteinberg M, et al. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000; 9: 401–5.
5. Crha I, Ventruba P, Žáková J, et al. Kryokonzervace spermatu před gonadotoxickou léčbou – 11 let zkušeností. Čes Gynek 2007; 72: 320–6.
6. Silva CA, Hallak J, Pasqualotto FF, et al. Gonadal function in male adolescents and young males with juvenile onset systemic lupus erythematosus. J Rheumatol 2002; 29: 2000–5.
7. Rueffer U, Breuer K, Josting A, et al. Male gonadal dysfunction in patients with Hodgkin‘s disease prior to treatment. Ann Oncol 2002; 13: 333.
8. Ataya K, Rao LV, Laurence E, et al. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide induced ovarian follicular depletion in Rhesus monkeys. Biol Reprod 1995; 52: 365–72.
9. Trasler JM, Hales BF, Robaire B. Chronic low dose cyclophosphamide treatment of adult male rats: effect on fertility, pregnancy outcome and progeny. Biol Reprod 1986; 34: 275–83.
10. Hoorweg-Nijman JJ, Delemarre-vande-Wall HA, DeWall FC, et al. Cyclophosphamide-induced disturbance of gonadotropin secretion manifesting testicular damage. Acta Endocrinol 1992; 126: 143–8.
11. Ghosh D, Das UB, Ghosh S, et al. Testicular gametogenic and steroidogenic activities in cyclophosphamide treated rat: a correlative study with testicular oxidative stress. Drug Chem Toxicol 2002; 25: 281–92.
12. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, et al. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004; 73: 39–85.
13. Matsui H, Mitsumori K, Yasuhara K, et al. Morphological evaluation of cyclophosphamide testicular toxicity in rats using quantitative morphometry of spermatogenic cycle stages. J Toxicol Sci 1995; 20: 407–14.
14. Elangovan N, Chiou TJ, Tzeng WF, et al. Cyclophosphamide treatment cause impairment of sperm and its fertilizing ability in mice. Toxicology 2006; 222: 60–70.
15. Katoh C, Kitajima S, Saga Y, et al. Assessment of quantitative dual-parameter flow cytometric analysis for the evaluation of testicular toxicity using cyclophosphamide and ethinylestradiol treated rats. J Toxicol Sci 2002; 27: 87–96.
16. Irvine DS, Twigg JP, Gordon EL et al. DNA integrity in human spermatozoa: relationships with semen duality. J Nadrol 2000; 21: 33–44.
17. Kangasniemi M, Huhtaniemi I, Meistrich ML. Failure of spermatogenesis to recover despite the presence of a spermatogonia in the irradiated LBNF1 rat. Biol Reprod 1996; 54: 1200–8.
18. Boldt J, Cline D, McLaughlin D. Human oocyte cryopreservation as an adjunct to IVF-embryo transfer cycles. Hum reprod 2003; 18: 1250–5.
19. Quintans CJ, Donaldson MJ, Bartolino MV, et al. Birth of two babies oocytes that were cryopreserved in a choline-based freezing medium. Hum Reprod 2002; 17: 3149–52.
20. Marrs RP, Greene J, Stone BA. Potential factors affecting embryo survival and clinical outcome with cryopreserved pronuclear human embryos. Am J Obstet Gynecol 2004; 190: 1766–71; discussion 1771–2.
21. DęAngelo A, Amso NN. Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. Hum Reprod 2002; 17: 2787–94.
22. Meirow D, Fasouliotis SJ, Nugent D, et al. A laparoscopic technique for obtaining ovarian cortical biopsy specimens for fertility conservation in patients with cancer. Fertil Steril 1999; 71: 948–51.
23. Donnez J, Bassil S. Indications for cryopreservation of ovarian tissue. Hum Reprod Update 1998; 4: 248–59.
24. Oktay K. Ovarian tissue cryopreservation and transplantation: preliminary findings and implications for cancer patients. Hum Reprod Update 2001; 7: 526–34.
25. Rutherford AJ, Gosden RG. Ovarian tissue cryopreservation: a practical option? Acta Paediatr 1999; 88: 13–8.
26. Hovatta O. Methods for cryopreservation of human ovarian tissue. Reprod Biomed Online 2005; 10: 729–34.
27. Newton H, Aubard Y, Rutherford A, et al. Low temperature storage and grafting of human ovarian tissue. Hum Reprod 1996;11: 1487–91.
28. Newton H, Fisher J, Arnold JR, et al. Permeation of human ovarian tissue with cryoprotective agents in preparation for cryopreservation. Hum Reprod 1998; 13: 376–80.
29. Gook DA, Edgar DH, Borg J, et al. Oocyte maturation, follicle rupture and luteinization in human cryopreserved ovarian tissue following xenografting. Hum Reprod 2003; 18: 1772–81.
30. Candy CJ, Wood MJ, Whittingham DG. Restoration of a normal reproductive lifespan after grafting of cryopreserved mouse ovaries. Hum Reprod 2000; 15: 1300–4.
31. Almodin CG, Minguetti-Camara VC, Meister H, et al. Recovery of fertility after grafting of cryopreserved germinative tissue in female rabbits following radiotherapy. Hum Reprod 2004; 19: 1287–93.
32. Candy CJ, Wood MJ, Whittingham DG. Follicular development in cryopreserved marmoset ovarian tissue after transplantation. Hum Reprod 1995; 10: 2334–8.
33. Kim SS, Yang HW, Kang HG, et al. Quantitative assessment of ischemic tissue damage in ovarian cortical tissue with or without antioxidant (ascorbic acid) treatment. Fertil Steril 2004; 82: 679–85.
34. Oktay K, Buyuk E, Veeck L, et al. Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet 2004; 363: 837–40.
35. Oktay K, Tilly J. Livebirth after cryopreserved ovarian tissue autotransplantation. Lancet 2004; 364: 2091–2; author reply 2092–3.
36. Bedaiwy MA, Falcone T. Ovarian tissue banking for cancer patients: reduction of post-transplantation ischaemic injury: intact ovary freezing and transplantation. Hum Reprod 2004; 19: 1242–4.
37. Blumenfeld Z. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and –B as markers. Mol Cell Endocrinol 2002; 187: 93–105.
38. Practice Committee of the American Society for Reproductive Medicine. Ovarian tissue and oocyte cryopreservation. Fertil Steril 2004; 82: 993–8.
39. Martinez-Madrid B, Dolmans MM, Van Langendockt A, et al. Freeze-thawing intact human ovary with its vascular pedicle with a passive cooling device. Fertil Steril 2004; 82: 1390–4.
40. Schilsky R, Sherins R, Hubbard S, et al. Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkinęs disease. Am J Med 1981; 71: 552–556.
41. Blumenfeld Z. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and –B as markers. Mol Cell Endocrinol 2002; 187: 93–105.
42. Blumendfeld Z. Fertility after treatment for Hodgkinęs disease. Ann Oncol 2002; 13(Suppl 1): 138–47.
43. Pritchard KI. GnRH analogues and ovarian ablation: their integration in the adjuvant strategy. Recent Results Cancer Res 1998; 152: 285–97.
44. Manger K, Wildt L, Kalden JR, et al. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study Autoimmun Rev 2006; 5: 269–72.
45. Mardešič T, Šnajderová M, et al. Protocol combining GnRH agonists and GnRH antagonists for rapid supression and prevention of gonadal damage during cytotoxic therapy. Eur J Gynaecol Oncol 2004; 25: 90–2.
46. Huser M, Crha I, Hudecek R, et al. Ovarian tissue cryopreservation – new opportunity to preserve fertility in female cancer patients. Eur J Gynaecol Oncol 2007; 8: 49–55. Review.
47. Huser M, Višňová H, Ventruba P, et al. Možnosti ochrany reprodukčních funkcí u žen podstupujících chemoterapii pro hematologickou malignitu. Prakt gyn 2006; 9: 6–8.
48. Huser M, Juránková E, Crha I, et al. Kryokonzervace ovariální tkáně – šance na záchranu fertility žen s nádorovým onemocněním. Čes Gynek 2007; 72: 68–73.
49. Ortin TT, Shoshlak CA, Donaldson SS. Gonadal status and reproductive function following treatmen for Hodgkinęs disease in childhood: The Stanford experience. Int J Radiol Oncol Biol Phys 1990; 19: 873–80.
50. Blumenfeld Z. Gender diference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy.Minerva Endocrinol 2007; 32: 23–34.
51. Oh MS, Chang MS, Park W, et al. Yukmijihwang-tang protects against cyclophosphamide-induced reproductive toxicity. Reprod Toxicol 2007; 24: 365–70.
52. Selvakumar E, Prahalathan C, Sudharsan PT, et al. Chemoprotective effect of lipoic acid against cyclophosphamide-induced changes in the rat sperm. Toxicology 2006; 217: 71–8.
53. Selvakumar E, Prahalathan C, Sudharsan PT, et al. Protective effect of lipoic acid on cyclophosphamide-induced testicular toxicity. Clin Chim Acta 2006; 367: 114–9.
54. Paynter SJ. Current status of the cryopreservation of human unfertilized oocytes. Human Reprod Update 2000; 6: 449–56.